Identification of CD8+ Immunogenic Peptides for Vaccine Design against Nipah Virus in Humans.

Pankaj Suden, Inderpal Singh, Chitrakshi Chopra, Malvika Mehta, Ratna Chandra, Indu Bhushan

Abstract read

In one paragraph

Article in Iranian journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pankaj SudenSchool of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.

Inderpal SinghSchool of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.

Chitrakshi ChopraSchool of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.

Malvika MehtaSchool of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.

Ratna ChandraSchool of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.

Indu BhushanSchool of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nipah virus is a pathogenic virus of ruinous zoonotic potential with inflated rate of mortality in humans. Methods: Considering the emerging threat of this pandemic virus, the present investigation amid to design vaccine by using the bioinformatics tools such as host and virus codon usage analysis, CD8+ peptide prediction, immunogenicity/allergenicity/toxicity, MHC-I allele binding prediction and subsequent population coverage and MHC-I-peptide docking analysis. Results: In this study (conducted in 2022 at School of Biotechnology, Katra, India), a set of 11 peptides of the structural proteins of Nipah Virus were predicted and recognized by the set of MHC-I alleles that are expressed in 92% of the global human population. Conclusion: The strong interactions between these peptides and the MHC-I protein suggest them as strong peptide candidates for the development of vaccine against Nipah Virus.

Indexed as

ImmunogenicpeptidesMolecular dynamicsNipah virusVaccine designZoonotic virus

Identifiers

PMID39759209

PMCPMC11693797

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.